1 – 9 of 9
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
(
- Contribution to journal › Article
- 2022
-
Mark
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS) : Protocol for a randomized controlled trial
(
- Contribution to journal › Article
-
Mark
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke) : an international, randomised, double-blind, placebo-controlled, phase 2b trial
(
- Contribution to journal › Article
- 2020
-
Mark
Characteristics of Recurrent Ischemic Stroke after Embolic Stroke of Undetermined Source : Secondary Analysis of a Randomized Clinical Trial
(
- Contribution to journal › Article
- 2019
-
Mark
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status : The NAVIGATE ESUS Trial
(
- Contribution to journal › Article
- 2018
-
Mark
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
(
- Contribution to journal › Article
- 2016
-
Mark
Overcoming global challenges in stroke prophylaxis in atrial fibrillation : The role of non-vitamin K antagonist oral anticoagulants
(
- Contribution to journal › Scientific review
-
Mark
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source : Design of the NAVIGATE ESUS randomized trial
(
- Contribution to journal › Article
- 2013
-
Mark
Granulocyte Colony-Stimulating Factor in Patients With Acute Ischemic Stroke: Results of the AX200 for Ischemic Stroke Trial.
(
- Contribution to journal › Article